within Pharmacolibrary.Drugs.ATC.L;

model L01EB01_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.00041499999999999995,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.014666666666666666,
    Tlag           = 9.12,            
    Vdp             = 5.14,
    k12             = 162,
    k21             = 162
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EB01_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gefitinib is an oral, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR mutations. It is approved and widely used for advanced NSCLC therapy.</p><h4>Pharmacokinetics</h4><p>Population PK in Chinese NSCLC patients, both sexes, median age ~55; normal hepatic and renal function.</p><h4>References</h4><ol><li><p>Rahman, AF, et al., &amp; Kassem, MG (2014). Gefitinib. <i>Profiles of drug substances, excipients, and related methodology</i> 39 239–264. DOI:<a href=\"https://doi.org/10.1016/B978-0-12-800173-8.00005-2\">10.1016/B978-0-12-800173-8.00005-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24794908/\">https://pubmed.ncbi.nlm.nih.gov/24794908</a></p></li><li><p>Culy, CR, &amp; Faulds, D (2002). Gefitinib. <i>Drugs</i> 62(15) 2237–2250. DOI:<a href=\"https://doi.org/10.2165/00003495-200262150-00008\">10.2165/00003495-200262150-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12381224/\">https://pubmed.ncbi.nlm.nih.gov/12381224</a></p></li><li><p>Yasumuro, O, et al., &amp; Namiki, N (2018). Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 48(11) 1106–1112. DOI:<a href=\"https://doi.org/10.1080/00498254.2017.1396379\">10.1080/00498254.2017.1396379</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29057719/\">https://pubmed.ncbi.nlm.nih.gov/29057719</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EB01_1;
